Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 2/20 | 0.59 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.59 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13886178 | 0.82 | PSMB5 (0.61) | PSMB5CTSLCTSBCTSS | |
| SCHEMBL8308836 | 0.81 | CTSS (0.70) | PSMB5PSMB1PSMB2CTSLCTSB | |
| SCHEMBL23154438 | 0.79 | L3MBTL1 (0.68) | PSMB5CTSLCTSBCTSSPOLB | |
| SCHEMBL7354817 | 0.79 | PSMB1 (0.52) | PSMB5PSMB1PSMB2GAAPKM | |
| SCHEMBL8309375 | 0.78 | PSMB1 (0.52) | PSMB5PSMB1PSMB2GAAPKM | |
| SCHEMBL8309254 | 0.78 | PSMB1 (0.49) | PSMB5PSMB1PSMB2GAAPKM | |
| SCHEMBL25000564 | 0.77 | MMP1 (0.63) | PSMB5 | |
| SCHEMBL7354824 | 0.77 | ALDH1A1 (0.51) | PSMB5PSMB1PSMB2GAAPKM | |
| SCHEMBL25139508 | 0.77 | MMP1 (0.63) | PSMB5 | |
| SCHEMBL7358007 | 0.77 | PSMB1 (0.49) | PSMB5PSMB1PSMB2GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MINERVA BIOTECHNOLOGIES CORPORATION | 2008-03-13 | — | — | US | disclosed |
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MINERVA BIOTECHNOLOGIES CORPORATION | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MUC1, CD44, TP53 | PSMB5 2361/4885PSMB1 2578/4885PSMB2 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.